Citations

Clear

79 citation(s) found for "Johnson, Matthew".

Infrapopliteal Segments on Lower Extremity CTA: Prospective Intraindividual Comparison of Energy-Integrating Detector CT and Photon-Counting Detector CT
Yalon, Mariana , Thorne, Jamison E. , Lee, Yong S. , Johnson, Matthew P. , Esquivel, Andrea , Rajiah, Prabhakar Shantha, Inoue, Akitoshi , Leng, Shuai , McCollough, Cynthia H. , Fletcher, Joel G. , Rajiah, Prabhakar

Mayo Clinic

American Journal of Roentgenology | December 20, 2023 | Volume: 222 | Issue: 3 | Pages: No page available

10.2214/ajr.23.29778 | PMID 37991334 Get It

Abstract 15321: Association Between Cardiovascular Risk Factors, Social Determinants of Health and Cardio-Ankle Vascular Index (CAVI) Scores Among African-American Adults: The FAITH! Heart Health+ (HH+) Study
Thomas, Victoria E, Lalika, Mathias , Mccoy, Carrie, Johnson, Matthew P. , Thomas, Victoria E. , Kullo, Iftikhar J. , McCoy, Carrie R, Hayes, Sharonne N. , Jones, Clarence , Cooper, Lisa A. , Patten, Christi A. , Brewer, LaPrincess C.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.15321 Get It

Background Cardio-ankle vascular index (CAVI) is a measure of arterial stiffness associated with cardiovascular (CV) events and mortality. African American (AA) adults have a higher prevalence of CV risk factors (RFs) and adverse social determinants of health (SDOH) leading to a higher CV mortality risk than White adults. These disparities may be associated with arterial stiffness, however limited research exists on the association of CV RFs, SDOH, and CAVI among AAs. Hypotheses We hypothesized that CV RFs (eg, diabetes) and SDOH (eg, income) would be associated with CAVI among AA adults. Our secondary hypothesis was that AA adults would have a higher prevalence of abnormal CAVI scores (≥8.0) than White adults. Methods In the FAITH! HH+ study, CAVI measurements, CV RFs, and SDOH surveys were obtained. We collected CAVI readings and CV RFs from a secondary cohort of White adults (n=600), referred for echocardiography and without structural cardiac disease. The association of CV RFs, SDOH and CAVI scores among AAs was assessed via ANOVA and univariable linear regression. We compared CV RFs among both cohorts using Chi-squared tests and ANOVA, followed by comparing CAVI scores between cohorts using a multivariable linear regression model. Results In total, 48 AAs were included from the FAITH! HH+ cohort (mean age [SD]: 54.2 [11.5] years, 67.4% women). There was no significant association between CV RFs or SDOH with CAVI scores. In the 600 White adults assessed, mean age was 59.5 [14.7] years and 45.7% were women. Compared to White adults, AA participants had a lower burden of hyperlipidemia (43.5% vs 61.4%; p=0.017), but a higher burden of hypertension (73.9% vs 57.7%; p=0.031), diabetes (28.3% vs 9.3%; p<0.001), and obesity (71.7% obese vs 36.0%; p<0.001). There was no significant difference in CAVI scores between groups when adjusted for age, sex, and CV RFs (AA cohort: mean: 8.0 [1.4] vs White cohort: 8.4 [1.5]; p=0.790). Conclusions In this pilot study, SDOH and CV RFs were not associated with CAVI scores among AAs. There was no significant difference in CAVI scores between AA and White adults, despite a significantly higher burden of CV RFs in the AA cohort. Further studies are warranted to identify factors linked with onset and progression of arterial stiffness among AAs.
Hybrid Immunity Provides Protective Advantage Over Vaccination or Prior Remote Coronavirus Disease 2019 Alone
Virk, Abinash , Johnson, Matthew G. , Roellinger, Daniel , Scott, Christopher G. , Sampathkumar, Priya , Breeher, Laura E. , Swift, Melanie D. , Roellinger, Daniel L, Swift, Melanie D , Scott, Christopher , Breeher, Laura

Mayo Clinic

Open Forum Infectious Diseases | March 27, 2023 | Volume: 10 | Issue: 5 | Pages: No page available

10.1093/ofid/ofad161 | PMID 37180597 Get It

Abstract Background The protective efficacy of prior coronavirus disease 2019 (COVID-19) with or without vaccination remains unknown. This study sought to understand if 2 or more messenger RNA (mRNA) vaccine doses provide additional protection in patients with prior infection, or if infection alone provides comparable protection. Methods We conducted a retrospective cohort study of the risk of COVID-19 from 16 December 2020 through 15 March 2022, among vaccinated and unvaccinated patients of all ages with and without prior infection. A Simon-Makuch hazard plot illustrated the incidence of COVID-19 between groups. Multivariable Cox proportional hazards regression was used to examine the association of demographics, prior infection, and vaccination status with new infection. Results Among 101 941 individuals with at least 1 COVID-19 polymerase chain reaction test prior to 15 March 2022, 72 361 (71.0%) received mRNA vaccination and 5957 (5.8%) were previously infected. The cumulative incidence of COVID-19 was substantially higher throughout the study period for those previously uninfected and unvaccinated, and lowest for those previously infected and vaccinated. After accounting for age, sex, and the interaction between vaccination and prior infection, a reduction in reinfection risk was noted during the Omicron and pre-Omicron phases of 26% (95% confidence interval [CI], 8%–41%; P = .0065) to 36% (95% CI, 10%–54%; P = .0108), respectively, among previously infected and vaccinated individuals, compared to previously infected subjects without vaccination. Conclusions Vaccination was associated with lower risk of COVID-19, including in those with prior infection. Vaccination should be encouraged for all including those with prior infection, especially as new variants emerge and variant-specific booster vaccines become available.
Key Stakeholder Perspectives of Community Engagement Efforts and the Impact of the Covid-19 Pandemic
Huang, Lily , Cleveland, Tiera, Clift, Kristin , Egginton, Jason S. , Johnson, Matthew G. , Albertie, Monica, Cardenas, Lilliana D., Allyse, Megan , Barwise, Amelia , Pacheco-Spann, Laura, Phelan, Sean M. , Allyse, Megan A , Barwise, Amelia K , Clift, Kristin E , Pacheco-Spann, Laura M.

Mayo Clinic

Journal of Primary Care & Community Health | November 4, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221133076 | PMID 36331120 Get It

Introduction: The COVID-19 pandemic has disproportionally affected historically marginalized populations and their access to resources and healthcare. In times of crisis, authentic community engagement is more important than ever. This study was Phase 1 of a larger 3-phase study to conduct timely community-engaged research with community members to understand the disproportionate impact of COVID-19 on historically underserved communities. The objective of this work was to conduct key informant (KI) interviews (1) to understand community organizations perspectives about the role that large academic health centers play as they interface with community organizations to support their work, (2) to leverage KI’s expertise to identify needs and assets within the community, and (3) to inform both Phase 2 (focus group qualitative research) and Phase 3 (survey) of the broader study. Methods: A total of 24 key informants were identified through purposeful sampling and one-on-one semi-structured interviews were conducted across 4 states using video conferencing. Results: Barriers to access and lack of transparency were highlighted as major issues requiring reform—in particular, aggressive billing practices and insurance barriers exacerbated local distrust of medical institutions. KIs recognized the health institution’s support for testing and vaccination during the COVID-19 pandemic, but noted other significant gaps in care, especially regarding mental health support. Although communication with the health institution was consistent for some KIs, others experienced unsustained communication efforts that hindered cooperation and relationship building. Conclusions: Leaders in the community as key stakeholders can provide unique insights into the challenges and potential solutions required to promote health equity, and foster understanding between local communities and healthcare institutions.
PPV of the Molecular Breast Imaging Lexicon
Hunt, Katie N. , Conners, Amy Lynn , Samreen, Naziya , Rhodes, Deborah J. , Johnson, Matthew P. , Hruska, Carrie B.

Mayo Clinic

American Journal of Roentgenology | July 20, 2022 | Volume: 220 | Issue: 1 | Pages: 40-48

10.2214/ajr.21.27047 | PMID 35856455 Get It

Diagnostic Performance in Low- and High-Contrast Tasks of an Image-Based Denoising Algorithm Applied to Radiation Dose–Reduced Multiphase Abdominal CT Examinations
Voß, Benjamin, Lee, Nam Ju, Takahashi, Hiroaki , Kozaka, Kazuto , Heiken, Jay P. , Ehman, Eric C. , Vasconcelos, Rogerio N., Fidler, Jeff L. , Lee, Yong S. , Mileto, Achille , Johnson, Matthew P. , Baer‐Beck, Matthias, Weber, Nikkole M. , Michalak, Gregory J. , Halaweish, Ahmed F., Carter, Rickey E. , Inoue, Akitoshi , Voss, Benjamin A, Vasconcelos, Rogerio, Halaweish, Ahmed, Carter, Rickey E , Takahashi, Hiroaki , Lee, Nam Ju, Fidler, Jeff L. , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | June 22, 2022 | Volume: 220 | Issue: 1 | Pages: 73-85

10.2214/ajr.22.27806 | PMID 35731096 Get It

Estimating the Clinical Impact of Photon-Counting-Detector CT in Diagnosing Usual Interstitial Pneumonia
Inoue, Akitoshi , Johnson, Tucker F. , White, Darin , Cox, Christian W. , Hartman, Thomas E. , Thorne, Jamison E. , Shanblatt, Elisabeth R. , Johnson, Matthew P. , Carter, Rickey E. , Lee, Yong S. , Fletcher, Joel G , Carter, Rickey E , Inoue, Akitoshi , Rajendran, Kishore , Leng, Shuai , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

Investigative Radiology | June 15, 2022 | Volume: 57 | Issue: 11 | Pages: 734-741

10.1097/rli.0000000000000888 | PMID 35703439 Get It

Objective The aim of this study was to evaluate the clinical impact of a higher spatial resolution, full field-of-view investigational photon-counting detector computed tomography (PCD-CT) on radiologist confidence in imaging findings and diagnosis of usual interstitial pneumonia (UIP) compared with conventional energy-integrating detector CT (EID-CT). Materials and Methods Patients suspected of interstitial lung disease were scanned on a PCD-CT system after informed consent and a clinically indicated EID-CT. In 2 sessions, 3 thoracic radiologists blinded to clinical history and scanner type evaluated CT images of the right and left lungs separately on EID- or PCD-CT, reviewing each lung once/session, rating confidence in imaging findings of reticulation, traction bronchiectasis, honeycombing, ground-glass opacities (GGOs), mosaic pattern, and lower lobe predominance (100-point scale: 0–33, likely absent; 34–66, indeterminate; 67–100, likely present). Radiologists also rated confidence for the probability of UIP (0–20, normal; 21–40, inconsistent with UIP; 41–60, indeterminate UIP; 61–81; probable UIP; 81–100, definite UIP) and graded image quality. Because a confidence scale of 50 represented completely equivocal findings, magnitude score (the absolute value of confidence scores from 50) was used for analysis (higher scores were more confident). Image noise was measured for each modality. The magnitude score was compared using linear mixed effects regression. The consistency of findings and diagnosis between 2 scanners were evaluated using McNemar test and weighted κ statistics, respectively. Results A total of 30 patients (mean age, 68.8 ± 11.0 years; M:F = 18:12) underwent conventional EID-CT (median CTDIvol, 7.88 mGy) and research PCD-CT (median CTDIvol, 6.49 mGy). The magnitude scores in PCD-CT were significantly higher than EID-CT for imaging findings of reticulation (40.7 vs 38.3; P = 0.023), GGO (34.4 vs 31.7; P = 0.019), and mosaic pattern (38.6 vs 35.9; P = 0.013), but not for other imaging findings (P ≥ 0.130) or confidence in UIP (34.1 vs 22.2; P < 0.059). Magnitude score of probability of UIP in PCD-CT was significantly higher than EID-CT in one reader (26.0 vs 21.5; P = 0.009). Photon-counting detector CT demonstrated a decreased number of indeterminate GGO (17 vs 26), an increased number of unlikely GGO (74 vs 50), and an increased number of likely reticulations (140 vs 130) relative to EID-CT. Interobserver agreements among 3 readers for imaging findings and probability of UIP were similar between PCD-CT and EID-CT (intraclass coefficient: 0.507–0.818 vs 0.601–0.848). Photon-counting detector CT had higher scores in overall image quality (4.84 ± 0.38) than those in EID-CT (4.02 ± 0.40; P < 0.001) despite increased image noise (mean 85.5 vs 36.1 HU). Conclusions Photon-counting detector CT provided better image quality and improved the reader confidence for presence or absence of imaging findings of reticulation, GGO, and mosaic pattern with idiosyncratic improvement in confidence in UIP presence.
An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC).
Banovac, Filip , Iyer, Renuka , Petroziello, Michael, Brown, Daniel W., Goff, Laura W. , Parikh, Nainesh, Toskich, Beau , Jiang, Yixing , Kulke, Matthew H. , Armstrong, Samantha , Johnson, Matthew S. , Shroff, Rachna T. , Woodhead, Gregory , He, Aiwu Ruth , Brown, Daniel, Kim, Richard D. , Kim, Kevin , Ganguli, Suvranu

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS4177-TPS4177

10.1200/jco.2022.40.16_suppl.tps4177 Get It

TPS4177 Background: The anti–PD-L1 antibody atezolizumab (ATEZO) prevents PD-L1 from interacting with PD-1 and B7.1, thus reinvigorating antitumor T cell activity. Anti-VEGF bevacizumab (BEV) increases dendritic cell maturation, enhances T cell infiltration, and reduces myeloid-derived suppressor cells and regulatory T cells in tumors. ATEZO + BEV is FDA approved for first-line treatment of advanced HCC based on the IMbrave 150 study. Locoregional radiotherapy (e.g., Y90 TARE) enhances the diversity of the intratumoral T cell receptor repertoire and increases tumor antigen release. We hypothesize that the Y90 TARE + BEV + ATEZO combination induces synergistic tumor killing and prolongs progression-free survival in patients (pts) receiving Y90 TARE (HR = 0.6 when compared to Y-90 TARE alone). Methods: Eligible pts have HCC that cannot be surgically resected (confirmed by pathology review), is at least BCLC stage B, and is outside Milan criteria. Other requirements include ECOG PS of 0-1 at screening, measurable disease by RECIST 1.1, no prior systemic therapy, and FLR estimated at ≥ 40% post local therapy. Pts must have a pretreatment liver biopsy taken and then be randomized 1:1 to TARE (Arm A) or TARE + ATEZO + BEV (Arm B). Pts will have TARE mapping followed by TARE treatment. In Arm B, pts will begin TARE treatment followed by BEV + ATEZO (4 wks [± 1 wk] later). Pts will have abdominal MRI or CT scans every 12 weeks and CT scans of the chest every 24 wks. The primary study objective is to assess and compare pts' progression-free survival (per mRECIST 1.1) in each study arm. The main secondary objective is to determine the safety and tolerability (CTCAE v5) of pts in Arm B. Exploratory objectives are to define the use of cellular and circulating biomarkers in the prediction of improved clinical outcomes of pts in Arm B. Symptoms experienced by pts in both arms using patient-reported outcomes will be assessed. Disease progression will be captured by both RECIST 1.1 and mRECIST. We plan to assess the safety of Y90 TARE + BEV + ATEZO in the first 10 pts randomized to Arm B for two cycles, and if there are no grade ≥ 3 unexpected toxicities possibly, probably, or definitely related to combined TARE + BEV + ATEZO, continue to accrue 128 pts in total (current enrollment n- = 5). Pts will continue study treatment (Arm B) for a total of 24 months from initiation of TARE or until intolerable toxicity or disease progression occur, whichever is earlier. Enrollment began in September 2020. Clinical trial information: NCT04541173.
Impact of dual-energy 50-keV virtual monoenergetic images on radiologist confidence in detection of key imaging findings of small hepatocellular carcinomas using multiphase liver CT
Voß, Benjamin, Khandelwal, Ashish , Wells, Michael , Venkatesh, Sudhakar K. , Lee, Yong S. , Johnson, Matthew P. , Fletcher, Joel G. , Voss, Benjamin A, Wells, Michael L, Inoue, Akitoshi , Fletcher, Joel G , Venkatesh, Sudhakar K

Mayo Clinic

Acta Radiologica | November 1, 2021 | Volume: 63 | Issue: 11 | Pages: 1443-1452

10.1177/02841851211052993 | PMID 34723681 Get It

Background Dual-energy virtual monoenergetic images can increase iodine signal, potentially increasing the conspicuity of hepatic masses. Purpose To determine if dual-energy 50-keV virtual monoenergetic images improve visualization of key imaging findings or diagnostic confidence for small (≤2 cm) hepatocellular carcinomas (HCC) at multiphase, contrast-enhanced liver computed tomography (CT). Material and Methods Patients with chronic liver disease underwent multiphase dual-energy CT imaging for HCC, with late arterial and delayed phase dual-energy 50-keV images reconstructed. Two non-reader subspecialized gastrointestinal (GI) radiologists established the reference standard, determining the location and diagnosis of all hepatic lesions using predetermined criteria. Three GI radiologists interpreted mixed kV CT images without or with dual-energy 50-keV images. Radiologists identified potential HCCs and rated their confidence (0–100 scales) in imaging findings of arterial enhancement, enhancing capsule, tumor washout, and LI-RADS 5 (2018) category. Results In total, 45 patients (14 women; mean age = 59.5 ± 10.9 years) with chronic liver disease were included. Of them, 19 patients had 25 HCCs ≤2 cm (mean size = 1.5 ± 0.4 cm). There were 17 LI-RADS 3 and 4 lesions and 19 benign lesions. Reader confidence in imaging findings of arterial enhancement, enhancing capsule, and non-peripheral washout significantly increased with dual-energy images ( P ≤ 0.022). Overall confidence in HCC diagnosis increased significantly with dual-energy 50-keV images (52.4 vs. 68.8; P = 0.001). Dual-energy images demonstrated a slight but significant decrease in overall image quality. Conclusion Radiologist confidence in key imaging features of small HCCs and confidence in imaging diagnosis increases with use of dual-energy 50-keV images at multiphase, contrast-enhanced liver CT.